Comparative Pharmacology
Head-to-head clinical analysis: DELTASONE versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTASONE versus TEXACORT.
DELTASONE vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, leading to altered gene expression and suppression of inflammatory mediators, immune cells, and cytokine production.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
5-60 mg orally once daily or divided twice daily; dose individualized based on condition and response.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
The terminal elimination half-life of prednisolone (active form) is 2.1–3.5 hours. In clinical context, this short half-life supports once-daily to twice-daily dosing for anti-inflammatory effects, but adrenal suppression can persist longer due to receptor binding.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Prednisone is a prodrug converted to prednisolone. Prednisolone is metabolized primarily in the liver. Renal excretion of unchanged drug is negligible (<1%). Metabolites are excreted renally (approximately 80% as glucuronides and sulfates) and to a small extent in feces (<5%). Biliary excretion is minimal.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid